Table 2.
Characteristics of the 32 study participants with cardiotoxicity (cardiotoxic group).
| Characteristics | No. of patients | % |
|---|---|---|
| Age at diagnosis of cardiotoxicity, years | 11.2 (6.4–14.9) | |
| Interval between anthracycline completion and cardiotoxicity, months | 13.1 (1.5–29.3) | |
| Onset of cardiotoxicity | ||
| Acute | 3 | 9.4 |
| Early | 12 | 37.5 |
| Late | 17 | 53.1 |
| Echocardiographic parameters | ||
| LV FS, % | 22.9 (18.6–26.4) | |
| LV FS z-score | −4.30 (−3.33 to −6.69) | |
| LVEDD, mm | 44.7 (40.4–49.7) | |
| LVESD, mm | 34.0 (29.4–39.9) | |
| Cardiotoxicity treatment | ||
| Inotropic support | 5 | 15.6 |
| Diuretics | 10 | 31.3 |
| Angiotensin-converting enzyme inhibitors | 14 | 43.8 |
| Beta blockers | 4 | 12.5 |
| Mineralocorticoid receptor antagonists |
6 | 18.8 |
| Digoxin | 9 | 28.1 |
| Mortality | ||
| All-cause mortality | 15 | 46.9 |
| Cardiac mortality | 3 | 9.4 |
| Follow-up duration, years | 3.6 (1.11–11.8) | |
Values represent median (IQR) or number (percentage).